CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

Nov 16, 2022

Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK
- Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023
Strengthening oncology position based on preparations for new clinical studies with mRNA-based cancer vaccine candidates and positive Phase 1 data on CV8102
- Two proof-of-principle studies planned in 2023 to validate and optimize second-generation mRNA backbone in oncology
- Phase 1 expansion study of non-coding RNA-based candidate CV8102 confirms safety and strong immuno-modulatory characteristics
First manufacturing licenses for The RNA Printer® in oncology expected, subject to regulatory approval; applications submitted to regulatory authorities in Q4 2022
Driving innovation at the 10^th International mRNA Health Conference with data on novel LNP delivery system and therapeutic approaches for diseases with high unmet medical need
Cash and cash equivalents position of €540.9 million as of September 30, 2022; driven mainly by proceeds related to transfer of production capacity to GSK

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.